(Q37731432)

22 August 2017

1 reference

title

Should we measure C-reactive protein on earth or just on JUPITER? (English)

1 reference

22 August 2017

Ambareesh Bajpai

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6653384&resulttype=core&format=json

15 May 2020

Abhinav Goyal

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6653384&resulttype=core&format=json

15 May 2020

Laurence Sperling

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6653384&resulttype=core&format=json

15 May 2020

publication date

1 April 2010

1 reference

22 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6653384&resulttype=core&format=json

15 May 2020

volume

33

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6653384&resulttype=core&format=json

15 May 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6653384&resulttype=core&format=json

15 May 2020

page(s)

190-198

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6653384&resulttype=core&format=json

The effect of including C-reactive protein in cardiovascular risk prediction models for women.

15 May 2020

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1002%2FCLC.20681

von Willebrand Factor, C-Reactive Protein, and 5-Year Mortality in Diabetic and Nondiabetic Subjects

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1002%2FCLC.20681

Associations of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly

21 January 2018

1 reference

12 December 2020

Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators

1 reference

12 December 2020

von Willebrand factor, C-reactive protein, and 5-year mortality in diabetic and nondiabetic subjects: the Hoorn Study

1 reference

12 December 2020

Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses

1 reference

12 December 2020

Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events

1 reference

12 December 2020

Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study

1 reference

12 December 2020

Improving coronary heart disease risk assessment in asymptomatic people: role of traditional risk factors and noninvasive cardiovascular tests

1 reference

12 December 2020

Age and duration of follow-up as modulators of the risk for ischemic heart disease associated with high plasma C-reactive protein levels in men.

1 reference

12 December 2020

C-reactive protein and myocardial infarction

1 reference

12 December 2020

Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study

1 reference

12 December 2020

C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: Phosphorylcholine of oxidized phospholipids

1 reference

12 December 2020

Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events

1 reference

12 December 2020

Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association

1 reference

12 December 2020

The relation of C-reactive protein levels to total and cardiovascular mortality in older U.S. women

1 reference

12 December 2020

C-Reactive Protein, Interleukin-6, and Fibrinogen as Predictors of Coronary Heart Disease

1 reference

12 December 2020

The value of C-reactive protein in cardiovascular risk prediction: the Rotterdam Study

1 reference

12 December 2020

Prevalence of conventional risk factors in patients with coronary heart disease

1 reference

12 December 2020

Inflammatory markers and onset of cardiovascular events: results from the Health ABC study

1 reference

12 December 2020

Lipoprotein-associated phospholipase A2, high-sensitivity C-reactive protein, and risk for incident coronary heart disease in middle-aged men and women in the Atherosclerosis Risk in Communities (ARIC) study

1 reference

12 December 2020

Possible protective role for C-reactive protein in atherogenesis: complement activation by modified lipoproteins halts before detrimental terminal sequence

1 reference

12 December 2020

C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease

1 reference

12 December 2020

Interleukin-6, fibrin D-dimer, and coagulation factors VII and XIIa in prediction of coronary heart disease

1 reference

12 December 2020

C-reactive protein, fibrin D-dimer, and risk of ischemic heart disease: the Caerphilly and Speedwell studies

1 reference

12 December 2020

Inflammatory markers and the risk of coronary heart disease in men and women

1 reference

12 December 2020

Fluctuating Inflammatory Markers in Patients With Stable Ischemic Heart Disease

1 reference

12 December 2020

C-reactive protein in the prediction of cardiovascular and overall mortality in middle-aged men: a population-based cohort study

1 reference

12 December 2020

Distribution of C-reactive protein values in the United States

1 reference

12 December 2020

Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial

1 reference

12 December 2020

C-reactive protein and the 10-year incidence of coronary heart disease in older men and women: the cardiovascular health study

1 reference

12 December 2020

Non-HDL cholesterol, apolipoproteins A-I and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women

1 reference

12 December 2020

C-reactive protein and risk of cardiovascular disease in men and women from the Framingham Heart Study

1 reference

12 December 2020

C-reactive protein and the acute-phase response

1 reference

12 December 2020

Increased concentrations of C-reactive protein and IL-6 but not IL-18 are independently associated with incident coronary events in middle-aged men and women: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002.

1 reference

12 December 2020

Development and validation of improved algorithms for the assessment of global cardiovascular risk in women: the Reynolds Risk Score.

1 reference

12 December 2020

C-reactive protein and coronary heart disease: a critical review

1 reference

12 December 2020

Genetically elevated C-reactive protein and ischemic vascular disease

1 reference

12 December 2020

C-reactive protein and parental history improve global cardiovascular risk prediction: the Reynolds Risk Score for men.

1 reference

12 December 2020

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein

1 reference

12 December 2020

Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial

1 reference

12 December 2020

A randomized trial of rosuvastatin in the prevention of venous thromboembolism

1 reference

12 December 2020

Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association

1 reference

12 December 2020

Rosuvastatin in the prevention of stroke among men and women with elevated levels of C-reactive protein: justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER).

1 reference

12 December 2020

From here to JUPITER: identifying new patients for statin therapy using data from the 1999-2004 National Health and Nutrition Examination Survey

1 reference

12 December 2020

Effect of C-reactive protein on platelet-activating factor-induced platelet aggregation and membrane stabilization

1 reference

12 December 2020

Binding of human C4 to C-reactive protein-pneumococcal C-polysaccharide complexes during activation of the classical complement pathway

1 reference

12 December 2020

Solid phase radioimmunoassays for human C-reactive protein

1 reference

12 December 2020

Metabolic and scintigraphic studies of radioiodinated human C-reactive protein in health and disease

1 reference

12 December 2020

Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men

1 reference

12 December 2020

Identifiers

DOI

10.1002/CLC.20681

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6653384&resulttype=core&format=json

15 May 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC6653384&resulttype=core&format=json

15 May 2020

1 reference